Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khalisa Syeda

Pediatric Cardiology Dothan, AL Doctor of Osteopathy

NPI 1326474438 CMS profile 2781989

540 Westgate Pkwy, Dothan, AL 36303

Open in the dashboard

General payments

$6,205

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Khalisa Syeda of Dothan, AL is reported in the CMS Open Payments database as having received $6,205 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Pediatric Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $346 12
2024 General $271 14
2023 General $229 11
2022 General $512 21
2021 General $276 14
2020 General $135 9
2019 General $4,435 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khalisa Syeda
  • Pediatric Cardiology median
  • Middle half of Pediatric Cardiology
  • National median

In program year 2025, general payments to Khalisa Syeda were reported at $346. Among 1,168 Pediatric Cardiology profiles paid that year, the median was $146 and the middle half received between $47 and $670.

Show as a table
Year Khalisa Syeda Pediatric Cardiology median Middle half National median
2019 $4,435 $124 $35–$516 $163
2020 $135 $70 $23–$326 $114
2021 $276 $112 $27–$445 $132
2022 $512 $129 $36–$680 $149
2023 $229 $149 $38–$826 $160
2024 $271 $131 $37–$652 $164
2025 $346 $146 $47–$670 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,907 7 payments
  2. Medtronic Vascular, Inc. $1,477 9 payments
  3. Genzyme Corporation $308 12 payments
  4. QOL Medical, LLC $301 10 payments
  5. Jazz Pharmaceuticals Inc. $229 9 payments
  6. Amgen Inc. $148 6 payments
  7. Dexcom, Inc. $145 9 payments
  8. Xeris Pharmaceuticals, Inc. $106 5 payments
  9. AbbVie, Inc. $84 6 payments
  10. Alcresta Therapeutics, Inc. $76 1 payment
  11. Other $423 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,381 5 payments
  2. Food and Beverage $2,816 93 payments
  3. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. General Therapies $2,907 7 payments
  2. DUPIXENT $308 12 payments
  3. Sucraid $301 10 payments
  4. XYWAV $205 8 payments
  5. Dexcom G6 Transmitter $109 7 payments
  6. TEZSPIRE $97 4 payments
  7. LUPRON DEPOT $84 6 payments
  8. RELIZORB $76 1 payment
  9. Epidiolex $64 4 payments
  10. GVOKE PFS $61 3 payments
  11. Other $552 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Cardiology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record